
    
      This RWS study is to evaluate the feasibility, preliminary safety and performance of Rezūm
      system in BPH treatment in China, to generate local real world data from a Chinese BPH
      population.

      The Rezūm System is intended to relieve symptoms, obstructions, and reduce prostate tissue
      associated with BPH. It is indicated for men ≥50 years of age with a prostate volume ≥ 30cm3
      and ≤80cm3. The Rezūm System is also indicated for treatment of prostate with hyperplasia of
      the central zone and/or a median lobe.
    
  